AstraZeneca PLC (AZN.LN) Wednesday announced the sale of its Alderley Park site on a former country estate in Cheshire, U.K., as part of a plan announced last March to set up a new research and development base in Cambridge in 2016.
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Does Pharma's Emphasis On External Sourcing Of Drugs Represent A Strategic Shift Away From Internal Research?Yahoo 03/11 08:01 ET
Indian drugmaker Ranbaxy Laboratories Ltd is in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc's heartburn pill Nexium, a person with direct knowledge ...
The U.S. Food and Drug Administration has asked Regeneron and Sanofi (NasdaqGM: GCVRZ - news) to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. The drug, alirocumab, is part of a new class known as PCSK9 inhibitors designed to block a protein that maintains "bad" LDL cholesterol in the bloodstream. "We have not seen a neurocognitive adverse signal in the alirocumab data," Dr. Michael Aberman, Regeneron's vice president for strategy and investor relations, said in a telephone interview. "What the FDA asked us to do we don't expect to be difficult or time consuming," Aberman added.
The U.S. Food and Drug Administration has called for an assessment of potential neurocognitive side effects of an experimental cholesterol drug being developed by Regeneron and Sanofi (NasdaqGM: GCVRZ - news) , Sanofi said in its annual report on Friday. The regulatory filing sent shares of Regeneron down 8 percent in Nasdaq trading. U.S.-listed shares of France-based Sanofi were down 1 percent. The Sanofi statement repeated a filing made by Regeneron last month, in which the company said it had been advised by the FDA that the agency had become aware of neurocognitive adverse events associated with an experimental class of drugs known as PCSK9 inhibitors.
Eli Lilly and partner Boehringer Ingelheim's empagliflozin received Complete Response Letter (CRL)